Presentations emphasize preclinical and scientific improvements of bexotegrast program in main sclerosing cholangitis
SOUTH SAN FRANCISCO, Calif., June 23, 2023 (WORLD NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a scientific phase biotechnology business concentrated on finding and establishing unique therapies for the treatment of fibrosis, today revealed that it provided Phase 2a scientific information and preclinical information of bexotegrast (PLN-74809) program today as part of the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023, held June 21- 24, 2023. Bexotegrast, is an oral, little particle, dual-selective inhibitor of αvβ6 and αvβ1 integrins being established for the treatment of idiopathic lung fibrosis and main sclerosing cholangitis (PSC).
“PSC is a rare chronic autoimmune disease with no effective therapy, representing a large unmet need for new treatments. Our presentations this week discuss the early non-clinical work that support our ongoing Phase 2a clinical program. We look forward to sharing interim data from this trial in the third quarter,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
The research study style, standard demographics and blinded safety information from the 85 individuals randomized into the 40, 80 and 160 mg dosage mates or placebo existed from the continuous INTEGRIS-PSC Phase 2a research study. This research study is examining the safety, tolerability, and pharmacokinetics of bexotegrast in PSC.
Twelve-week information from this research study is anticipated in the 3rd quarter of 2023. Following a positive independent Data Safety Monitoring Board (DSMB) safety evaluation in the very first quarter, registration began in a Phase 2a trial of bexotegrast at 320 mg dosed daily for a minimum of 24 weeks, and approximately 48 weeks, in clients with PSC.
The following posters were chosen for addition in EASL’s Session Poster Tours.
The results of bexotegrast on specific cell populations were examined in fibrotic PSC and main biliary cholangitis (PBC) precision-cut liver pieces. Treatment with bexotegrast led to clear decreases in profibrogenic gene expression throughout several pathologic cell populations with a comparable degree of decrease in profibrogenic gene expression seen compared to a TGF-β receptor I kinase inhibitor. These results recommend a crucial function for the integrin-TGF-β activation path in fibrotic biliary illness and follow the anti-fibrotic system of action of bexotegrast.
animal and molecular MRI were utilized to non-invasively keep an eye on the results of αvβ6 and αvβ1 antagonism in a rat design of biliary fibrosis. Results revealed modifications in target expression and fibrosis in reaction to bile duct injury and treatment with a double integrin αvβ6/αvβ1 villain that were verified by timeless histological analysis. These information support the antifibrotic result of double αvβ6/αvβ1 integrin inhibition in biliary fibrosis.
Posters provided at the 2023 EASL Conference are available under the Publications area on Pliant’s website at https://pliantrx.com/publications.
Forward-Looking Statements
Statements consisted of in this news release relating to matters that are not historic realities are “positive declarations” within the significance of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “anticipate,” “expect,” “price quote,” “plan,” and comparable expressions (along with other words or expressions referencing future occasions, conditions, or scenarios) are planned to recognize positive declarations. These declarations consist of those relating to future advancement of bexotegrast and timing of future information from our scientific programs. Because such declarations handle future occasions and are based upon our present expectations, they undergo numerous dangers and unpredictabilities and real outcomes, efficiency or accomplishments of Pliant Therapeutics might vary materially from those explained in or indicated by the declarations in this news release. These positive declarations undergo dangers and unpredictabilities, consisting of those associated to the advancement and commercialization of our item prospects, consisting of any hold-ups in our continuous or organized preclinical or scientific trials, the effect of the COVID-19 pandemic on our business, operations, scientific supply and strategies, our dependence on 3rd parties for crucial elements of our advancement operations, the dangers fundamental in the drug advancement procedure, the dangers relating to the precision of our quotes of costs and timing of advancement, our capital requirements and the requirement for extra funding, and our capability to obtain and preserve copyright defense for our item prospects. These and extra dangers are gone over in the areas entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022, as upgraded by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which are available on the SEC’s website at www.sec.gov. Unless otherwise kept in mind, Pliant is offering this info since the date of this press release and does not carry out any commitment to update any positive declarations consisted of in this file as an outcome of brand-new info, future occasions or otherwise.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a scientific phase biopharmaceutical business concentrated on finding and establishing unique treatments for the treatment of fibrosis. Pliant’s lead item prospect, bexotegrast (PLN-74809), is an oral little particle double selective inhibitor of αvß6 and αvß1 integrins that remains in advancement in the lead indicators for the treatment of idiopathic lung fibrosis, or IPF, and main sclerosing cholangitis, or PSC. Bexotegrast has actually received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is presently performing a Phase 2a trial of bexotegrast in the PSC and is preparing a Phase 2b trial in IPF. Pliant has actually likewise established PLN-1474, a little particle, selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis. Pliant is starting a Phase 1 research study for its 3rd scientific program, PLN-101095, a little particle, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being established for the treatment of strong growths. In addition to scientific phase programs, Pliant presently has a preclinical program targeting muscular dystrophies. For extra info, please see: www.PliantRx.com. Follow us on social networks: Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
[email protected]
